Immuneel and Arogya Finance launch India’s first zero cost EMI program for Qartemi CAR-T Cell…
Immuneel Therapeutics, India's pioneering cell and gene therapy company, announced a strategic partnership with Arogya Finance to…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CAR-T cell therapy
THSTI, Miltenyi Biotec and BIRAC launch India’s first hands-on training on cell and gene therapy…
The initiative focuses on building India’s capacity in CAR-T cell therapy through practical training and industry-academia…
Indian Society for Clinical Research appoints Dr Seema Pai as President
Dr Seema Pai to lead ISCR as it marks 20 years, with new appointments to General Secretary and Treasurer roles
Immuneel Therapeutics launches Qartemi, a CAR T-cell therapy for Non-Hodgkin’s Lymphoma
Immuneel has collaborated with hospitals including Narayana Health, Apollo Hospitals, CMC Vellore, Manipal Hospitals among others…
Aurigene Oncology announces phase 1 results for India’s first CAR-T cell therapy in multiple Myeloma
SWASTH study reports clinical response in all patients; Drugs Controller General of India approves Phase 2 trial
Revolutionising cancer treatment: The promise of point-of-care CAR-T therapy
Dr Prudwidhar S, Country Medical Affairs Director, Miltenyi Biotec emphasises why successful implementation of CAR-T cell therapy…
US FDA gives record number of review designations to CRISPR drugs in 2023: GlobalData
Casgevy is the first CRISPR-based drug to receive marketing authorisation globally
ImmunoACT to lead journey of indigenous CAR-T cell therapy in India but market access a hurdle:…
As per ImmunoACT CEO, NexCAR19 will be available at a price of Rs 30-40 lakh ($36,000- $48,000), which is 1/10th of the cost of…
US FDA approves Bristol Myers Squibb’s CAR-T cell therapy Breyanzi for relapsed large B-cell…
In the pivotal phase-III Transform trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of…
Immuneel sets up cell therapy development and production facility in Narayana Hrudayalaya Health…
The facility will currently focus on autologous cell therapies including CAR-T cell therapy for lymphomas and leukaemias